Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Director Thomas J. Schall of Immuneering Corp (NASDAQ:IMRX) recently purchased 40,485 shares of Class A Common Stock, according to a Form 4 filing with the Securities and Exchange Commission. The transactions, which occurred on June 17, 2025, involved a total value of $89,277. The purchase comes as InvestingPro data shows the stock has fallen over 14% in the past week, though analyst price targets range from $1.50 to $21.00, suggesting significant potential volatility ahead.
The shares were bought at a weighted average price of $2.2052, in multiple trades through a broker-dealer at prices ranging from $2.16 to $2.24
In other recent news, Immuneering Corporation has announced promising results from its Phase 2a trial for the pancreatic cancer treatment, atebimetinib. The trial, which combines atebimetinib with modified gemcitabine/nab-paclitaxel, reported a 94% overall survival rate and 72% progression-free survival rate at six months, surpassing standard benchmarks. Following these results, Mizuho (NYSE:MFG) raised its price target for Immuneering to $10, maintaining an Outperform rating due to the drug’s favorable safety profile and potential as a best-in-class treatment. The company plans to increase trial enrollment to approximately 50 patients and aims to start a pivotal trial in 2026. Additionally, Immuneering has appointed Dr. Igor Matushansky as the new Chief Medical (TASE:BLWV) Officer to guide its clinical strategies. The company also held its Annual Meeting of Stockholders, electing three Class I directors and ratifying its accounting firm for the fiscal year. These developments highlight Immuneering’s ongoing efforts to advance its cancer treatment programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.